Mentice AB (publ) (MNTC.ST)
SEK 25.3
(1.61%)
SEK 25.3
(1.61%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -679 Thousand SEK | 90.33% |
| 2022 | -22.66 Million SEK | -22.44% |
| 2021 | -18.51 Million SEK | 41.4% |
| 2020 | -31.58 Million SEK | -13.6% |
| 2019 | -27.8 Million SEK | -272.42% |
| 2018 | 16.12 Million SEK | 146.57% |
| 2017 | 6.54 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 17.5 Million SEK | 175.29% |
| 2024 Q1 | -24.19 Million SEK | -759.27% |
| 2023 Q2 | 4.82 Million SEK | 4581.55% |
| 2023 Q1 | 103 Thousand SEK | -98.44% |
| 2023 FY | -2.19 Million SEK | 90.33% |
| 2023 Q4 | -2.81 Million SEK | -37.84% |
| 2023 Q3 | -2.04 Million SEK | -142.37% |
| 2022 Q2 | -18.69 Million SEK | -142.98% |
| 2022 Q1 | -7.69 Million SEK | -291.39% |
| 2022 FY | -22.66 Million SEK | -22.44% |
| 2022 Q4 | 6.6 Million SEK | 171.4% |
| 2022 Q3 | -9.24 Million SEK | 50.52% |
| 2021 Q1 | -12.84 Million SEK | -2773.38% |
| 2021 Q2 | -5.1 Million SEK | 60.22% |
| 2021 Q4 | 4.01 Million SEK | 169.44% |
| 2021 Q3 | -5.78 Million SEK | -13.29% |
| 2021 FY | -18.51 Million SEK | 41.4% |
| 2020 Q4 | -447 Thousand SEK | -146.81% |
| 2020 Q3 | 955 Thousand SEK | 106.32% |
| 2020 Q2 | -15.12 Million SEK | -320.03% |
| 2020 Q1 | -3.6 Million SEK | -142.94% |
| 2020 FY | -31.58 Million SEK | -13.6% |
| 2019 FY | -27.8 Million SEK | -272.42% |
| 2019 Q4 | 8.38 Million SEK | 189.6% |
| 2019 Q3 | -9.35 Million SEK | 26.33% |
| 2019 Q2 | -12.7 Million SEK | -17.57% |
| 2019 Q1 | -10.8 Million SEK | -147.57% |
| 2018 Q2 | -4.84 Million SEK | -125.1% |
| 2018 Q3 | 413 Thousand SEK | 108.53% |
| 2018 Q4 | 22.7 Million SEK | 5398.31% |
| 2018 FY | 16.12 Million SEK | 146.57% |
| 2018 Q1 | -2.15 Million SEK | 0.0% |
| 2017 FY | 6.54 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.55 Million SEK | 99.124% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 100.226% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 100.226% |
| Arcoma AB | 4.66 Million SEK | 114.571% |
| Bactiguard Holding AB (publ) | -131.93 Million SEK | 99.485% |
| BICO Group AB (publ) | -618.3 Million SEK | 99.89% |
| Boule Diagnostics AB (publ) | 39.27 Million SEK | 101.729% |
| CellaVision AB (publ) | 167.05 Million SEK | 100.406% |
| Clinical Laserthermia Systems AB (publ) | -65.93 Million SEK | 98.97% |
| Chordate Medical Holding AB (publ) | -29.57 Million SEK | 97.704% |
| C-Rad AB (publ) | 44.24 Million SEK | 101.535% |
| Duearity AB (publ) | -25.76 Million SEK | 97.364% |
| Dignitana AB (publ) | -15.02 Million SEK | 95.481% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 99.284% |
| Getinge AB (publ) | 3.81 Billion SEK | 100.018% |
| Scandinavian Real Heart AB (Publ) | -68.44 Million SEK | 99.008% |
| Iconovo AB (publ) | -45.77 Million SEK | 98.517% |
| Integrum AB (publ) | 6.51 Million SEK | 110.426% |
| Luxbright AB (publ) | -25.8 Million SEK | 97.369% |
| OssDsign AB (publ) | -91.95 Million SEK | 99.262% |
| Paxman AB (publ) | 12.61 Million SEK | 105.381% |
| Promimic AB (publ) | -9.11 Million SEK | 92.553% |
| Qlife Holding AB (publ) | -168.69 Million SEK | 99.598% |
| SciBase Holding AB (publ) | -53.93 Million SEK | 98.741% |
| ScandiDos AB (publ) | -13.48 Million SEK | 94.964% |
| Sectra AB (publ) | 518.49 Million SEK | 100.131% |
| Sedana Medical AB (publ) | -65.54 Million SEK | 98.964% |
| Senzime AB (publ) | -133.74 Million SEK | 99.492% |
| SpectraCure AB (publ) | -21.35 Million SEK | 96.82% |
| Stille AB | 44.95 Million SEK | 101.511% |
| Vitrolife AB (publ) | -3.58 Billion SEK | 99.981% |
| Xvivo Perfusion AB (publ) | 38.5 Million SEK | 101.763% |